Episurf Medical (Nasdaq: EPIS B) today announces that the company’s knee implant technology and clinical results will be presented at the 6th Annual Meeting of the UK Biological Knee Society, on January 30-31 in Cambridge, the United Kingdom. M.D. Ph.D. M. Högström at Sports Medicine Umeå, Sweden, has been invited to the meeting to give the presentation “Metal Mini Prosthesis for Focal Chondral Lesions”. The presentation is based on the clinical results from a European multicenter study with 100 patients in the “gap age”, 35-60 years old, that have undergone treatment of focal chondral defects using the knee implant Episealer®.
“A large multicentre study of the Episealer® implant is ongoing in six European countries, and we are very happy for the fact that clinical results from this study will be presented at this important meeting” says Pål Ryfors, CEO Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
CisionBlockPro\Cision\FeedItem Object
(
[HtmlCompanyInformation:protected] =>
[HtmlContact:protected] =>
[HtmlTitle:protected] => <h1><strong><span style="font-family:arial,helvetica,sans-serif">Clinical data for Episealer® to be presented at orthopaedic congress in The United Kingdom</span></strong></h1>
[HtmlHeader:protected] =>
[HtmlIntro:protected] =>
[Body:protected] => Episurf Medical (Nasdaq: EPIS B) today announces that the company’s knee implant technology and clinical results will be presented at the 6[th] Annual Meeting of the UK Biological Knee Society, on January 30-31 in Cambridge, the United Kingdom. M.D. Ph.D. M. Högström at Sports Medicine Umeå, Sweden, has been invited to the meeting to give the presentation “Metal Mini Prosthesis for Focal Chondral Lesions”. The presentation is based on the clinical results from a European multicenter study with 100 patients in the “gap age”, 35-60 years old, that have undergone treatment of focal chondral defects using the knee implant Episealer®.
“A large multicentre study of the Episealer® implant is ongoing in six European countries, and we are very happy for the fact that clinical results from this study will be presented at this important meeting” says Pål Ryfors, CEO Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
[HtmlBody:protected] => <p style="margin-bottom:10px"><span style="font-size:10pt"><span style="line-height:107%"><span style="font-family:arial,helvetica,sans-serif">Episurf Medical (Nasdaq: EPIS B) today announces that the company’s knee implant technology and clinical results will be presented at the 6<sup>th</sup> Annual Meeting of the UK Biological Knee Society, on January 30-31 in Cambridge, the United Kingdom. M.D. Ph.D. M. Högström at Sports Medicine Umeå, Sweden, has been invited to the meeting to give the presentation <em>“Metal Mini Prosthesis for Focal Chondral Lesions”</em>. The presentation is based on the clinical results from a European multicenter study with 100 patients in the “gap age”, 35-60 years old, that have undergone treatment of focal chondral defects using the knee implant Episealer®.</span></span></span></p>
<p style="margin-bottom:10px"><span style="font-size:10pt"><span style="line-height:107%"><span style="font-family:arial,helvetica,sans-serif"><em><span style="font-family:arial,helvetica,sans-serif">“A large multicentre study of the Episealer® implant is ongoing in six European countries, and we are very happy for the fact that clinical results from this study will be presented at this important meeting”</span></em> says Pål Ryfors, CEO Episurf Medical.</span></span></span></p>
<p style="font-family:arial,helvetica,sans-serif; font-size:10pt"><span style="font-size:10pt"><strong><span style="font-family:arial,helvetica,sans-serif">For more information, please contact:</span></strong></span></p>
<p style="font-family:arial,helvetica,sans-serif; font-size:10pt"><span style="font-size:10pt"><span style="font-family:arial,helvetica,sans-serif">Pål Ryfors, CEO, Episurf Medical</span><br>
<span style="font-family:arial,helvetica,sans-serif">Tel:</span><span style="font-family:arial,helvetica,sans-serif">+46 (0) 709 62 36 69</span><br>
<span style="font-family:arial,helvetica,sans-serif">Email: </span><a href="mailto:pal.ryfors@episurf.com"><span style="font-family:arial,helvetica,sans-serif">pal.ryfors@episurf.com</span></a></span></p>
<p style="font-family:arial,helvetica,sans-serif; font-size:10pt"><span style="font-size:10pt"><strong><span style="font-family:arial,helvetica,sans-serif">About Episurf Medical</span></strong></span></p>
<p style="font-family:arial,helvetica,sans-serif; font-size:10pt"><span style="font-size:10pt"><em><span style="font-family:arial,helvetica,sans-serif">Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.</span></em></span></p>
[ServiceCategories:protected] => Array
(
[0] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => Twitter
[Name:protected] => Twitter
[Value:protected] => 9341
)
[1] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => LinkedIn
[Name:protected] => LinkedIn
[Value:protected] => 12134
)
[2] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => Facebook
[Name:protected] => Facebook
[Value:protected] => 9307
)
)
[LogoUrl:protected] => https://mb.cision.com/Public/14691/logo/96c29c854b230ac3_org.png
[CompanyInformation:protected] =>
[Contact:protected] =>
[Header:protected] =>
[Keywords:protected] => Array
(
[0] => Episurf Medical
[1] => EpiSurf
[2] => Pål Ryfors
)
[QuickFacts:protected] => Array
(
)
[Categories:protected] => Array
(
)
[Videos:protected] => Array
(
)
[Files:protected] => Array
(
[0] => CisionBlockPro\Cision\File Object
(
[IsMain:protected] => 1
[MediaType:protected] => File
[Url:protected] => https://mb.cision.com/Main/14691/3023363/1185108.pdf
[FileName:protected] => wkr0006.pdf
[Title:protected] => Clinical data for Episealer® to be presented at orthopaedic congress in The United Kingdom
[Description:protected] => Clinical data for Episealer® to be presented at orthopaedic congress in The United Kingdom
[CreateDate:protected] => 2020-01-30T08:00:22.59Z
[Keywords:protected] => Array
(
)
[Extension:protected] => pdf
)
)
[Quotes:protected] => Array
(
)
[ExternalLinks:protected] => Array
(
)
[EmbeddedItems:protected] => Array
(
)
[Id:protected] => 3552579
[EncryptedId:protected] => 0AC9114D3182B9E9
[IsRegulatory:protected] =>
[PublishDate:protected] => 2020-01-30T08:00:00Z
[LastChangeDate:protected] => 2020-01-30T08:00:22.577Z
[Title:protected] => Clinical data for Episealer® to be presented at orthopaedic congress in The United Kingdom
[Intro:protected] =>
[IptcCode:protected] => 04016003
[InformationType:protected] => PRM
[LanguageCode:protected] => en
[CountryCode:protected] => se
[CanonicalUrl:protected] =>
[CisionWireUrl:protected] => https://news.cision.com/episurf/r/clinical-data-for-episealer--to-be-presented-at-orthopaedic-congress-in-the-united-kingdom,c3023363
[LanguageVersions:protected] => Array
(
)
[Images:protected] => Array
(
)
[Tickers:protected] => Array
(
[0] => stdClass Object
(
[Symbol] => EPIS B
[ISIN] => SE0003491562
[PrimaryListing] => 1
[IsShare] => 1
[MarketPlaceSymbol] => STO
[MarketPlaceName] => Stockholmsbörsen
[MarketPlaceBloombergCode] => SS
[MarketPlaceMarketWireCode] => OMX
[MarketPlaceIsRegulated] => 1
[MarketPlaceCountryCode] => SE
)
)
)